Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

PURPOSE: ABT-751 is an antimitotic and vascular disrupting agent with potent preclinical anticancer activity. We conducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in patients with recurrent advanced or metastatic non–small-cell lung cancer (NSCLC)....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rudin, Charles M., Mauer, Ann, Smakal, Martin, Juergens, Rosalyn, Spelda, Stanislav, Wertheim, Michael, Coates, Andrew, McKeegan, Evelyn, Ansell, Peter, Zhou, Xiangdong, Qian, Jane, Pradhan, Rajendra, Dowell, Barry, Krivoshik, Andrew, Gordon, Gary
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2011
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4672026/
https://ncbi.nlm.nih.gov/pubmed/21300929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5944
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados